Chronological differences in the beneficial effects of empagliflozin and of liraglutide on cardiovascular events (composite of cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke) in the EMPA-REG OUTCOME8 (A) and LEADER7 (B) trials. 95%CI, 95% confidence interval; HR, hazard ratio.
{}